4.6 Letter

Therapeutic drug monitoring in inflammatory bowel disease treatments

Journal

WORLD JOURNAL OF GASTROENTEROLOGY
Volume 28, Issue 15, Pages 1604-1607

Publisher

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v28.i15.1604

Keywords

Therapeutic drug monitoring; Inflammatory bowel disease; Biologic therapies; Reactive; Proactive; Cost-effective

Ask authors/readers for more resources

Biological drugs have become crucial in treating inflammatory bowel disease, and therapeutic drug monitoring (TDM) can maximize their effectiveness. Individualized TDM based on patients' disease severity and therapeutic goals can optimize treatment by adjusting dosage or converting drugs.
Recently, biological drugs have played a leading role in the treatment of inflammatory bowel disease, and therapeutic drug monitoring (TDM) may be useful in maximizing their effectiveness. TDM involves the measurement of serum drug and anti-drug antibodies concentrations as the basis for dosage adjustments or drug conversions to achieve a higher response rate. We believe that concentration thresholds should be individualized based on patients' disease severity, extent and phenotype, and therapeutic purposes should also be considered, with higher cut-offs mainly needed for endoscopic and fistula healing than for symptomatic remission. Proactive and reactive TDM can help optimize treatment, especially in patients receiving anti-tumour necrosis factor, and guide dose adjustment or drug conversion with lower cost. TDM is a promising approach to achieve precision medicine and targeted medicine in the future.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available